GITNUX MARKETDATA
Browse Our Category
Medical Conditions Disorders
Latest update:
Hodgkin Lymphoma Statistics
A modern snapshot of Hodgkin lymphoma statistics, where painless enlarged nodes lead the story for 70 to 80% of patients, yet PET CT staging reaches 94% sensitivity and the overall prognosis splits sharply by factors like ESR and bulky disease. You will also find the 2023 US incidence estimate of 8,570 new cases alongside key diagnostic and subtype rates such as nodular sclerosis in 70% of cases and the 5% chance of lymphoma showing up in the bone marrow at diagnosis.
Tendonitis Statistics
From rotator cuff changes that climb sharply after age 50 to tendon syndromes showing up as often as 2 to 3 per 1000 person years in general practice, this page connects the hidden scale of tendonitis related burden with recovery timelines that can swing from 6 to 12 weeks to beyond 6 months. You will also see how global musculoskeletal disability reaches 1.71 billion YLDs and why, even with millions seeking care in primary settings, many diagnoses like trigger finger and carpal tunnel still feel surprisingly common.
Hypothyroidism Statistics
Nearly 84% of US cases of hypothyroidism are still missed, even as NHANES data suggest overt disease affects about 0.3% of adults, leaving a wide gap between what labs define and what clinicians capture. This page puts those contrasts side by side with risks across life stages and triggers like diabetes, neck radiation, and Graves’ treatment, plus the practical timelines behind newborn screening and levothyroxine titration.
Lupus Statistics
From 200,000 estimated adults living with lupus in the U.S. to how hydroxychloroquine has become the guideline default, this page puts the most clinically useful trends side by side, including nephritis in about 30%–50% of adults and a 74% lower renal flare risk with rituximab versus cyclophosphamide. You will also see where risk spikes beyond the kidneys, from fatigue that up to 70% report to the unexpected burden of ED visits and ongoing delays to diagnosis.
Acromegaly Statistics
See why acromegaly is more than a hormone story as 70–90% of cases trace back to pituitary adenomas and biochemical remission means normalizing IGF-1 to age adjusted targets, not just improving symptoms. From microadenomas in 25% at diagnosis to a 5.0 year median delay to detection and cardiovascular, cancer, and sleep apnea risks that stay higher when GH and IGF 1 remain uncontrolled, this page turns treatment outcomes and tumor behavior into the timelines and probabilities you actually need.
Concussions In Sports Statistics
One page. One sobering mismatch. Even though 86% of U.S. high school athletes report receiving concussion education, 14% still did not, 16% were cleared to return the same day, and 34% think no symptoms means no concussion. You will also see how gaps in return to play and return to learn guidance show up across athletes, parents, coaches, and athletic trainers, right down to a measurable concussion rate in youth sports.
Sleep Paralysis Statistics
With lifetime prevalence estimates ranging from 5.5% pooled in population research to 37.8% in a Ghana community survey, sleep paralysis is anything but rare or uniform, and poor sleep quality can raise the odds by 1.4 times. Yet most episodes feel brief within minutes, people often cope without clinicians, and only 5% use wearable trackers, even as recurrent attacks and daytime impairment keep showing up.
Traumatic Brain Injury Statistics
A Traumatic Brain Injury can follow you far beyond the impact, with about 1 in 5 people reporting symptoms that last longer than a year. From 69 million people affected worldwide each year to post injury outcomes like poor long term recovery, sleep and mood problems, and even seizures, these statistics explain why TBI is both a clinical emergency and a long-term cost and care challenge.
Cystic Fibrosis Statistics
Cystic fibrosis is genetic, driven by CFTR variants on chromosome 7, yet the latest trial evidence makes the contrast startling with ivacaftor cutting pulmonary exacerbations by 55% and raising BMI, while modulators also nudge lung function and sweat chloride in measurable steps. This page also tracks what that progress costs and affects in real care and real markets, from the near universal lung disease rate of 98% to persistent chronic therapy use around 62% at 12 months and major spending pressures in the NHS and US.
Group Purchasing Organization Industry Statistics
See how 2024 GPO managed spend hit $402 billion for U.S. hospitals while average supply savings reach 13 to 16 percent for major systems and non-acute contracts deliver 11.8 percent savings, powered by compliance rates above 90 percent. It is a page built for buyers who want the sharp contrast between the headline discounts and the measurable, tech enabled savings that keep showing up quarter after quarter.
Pyromania Statistics
Pyromania may sound like arson, but the diagnosis depends on impulse control coding, careful comorbidity checks, and forensic inference rather than the fire reports that typically track suspected intent. With only 0 large-sample randomized controlled trials specifically for pyromania and estimates of impulse control problems in the general population around 2.5% to 3.0%, this page explains why rare case data, underdiagnosis, and mismatched classification systems make the true picture difficult to measure.
Global Breast Cancer Statistics
Breast cancer keeps rising in more developed regions even as access gaps in low and middle income countries translate lower incidence into 70% of deaths, and GLOBOCAN 2020 estimates 7.8 million people living with breast cancer after 5 years. You will also see how biomarker subtypes and prevention choices reshape outcomes, from the 42% mortality drop in the US to the 20% relative reduction in deaths from screening mammography.
Hcm Statistics
From HR and payroll tech growing to US$ 79.0 billion by 2032, to AI adoption reaching 80% of HR and talent operations by 2025, the Hcm statistics page shows where automation is already tightening compliance, cutting administrative rework, and reshaping talent management. You will see exactly how benefits governance and analytics priorities are pulling budgets toward systems that reduce errors, not just manage them.
Paroxysmal Nocturnal Hemoglobinuria Statistics
See how real world PNH outcomes shift after complement inhibition, from breakthrough intravascular hemolysis that stays in low single digit ranges with adherence and LDH monitoring to thromboembolism dropping from 1.9 annualized events per 100 patient years before therapy. Get a safety and quality of care reality check too, including meningococcal infection rates tracked post marketing alongside practical burden contrasts where ravulizumab maintenance every 8 weeks can mean about 6 infusions per year versus 26 for eculizumab, plus registry level gains like fatigue improvement in 63% of patients.
Seizure Statistics
Epilepsy remains a massive and measurable threat with about 30% to 50% of people still facing uncontrolled seizures and nearly 500,000 deaths worldwide each year linked to epilepsy, including SUDEP and seizure-related mortality. Get the figures on why control is so hard, from treatment resistance and missed medication to stigma, emergency care use, and device and surgery outcomes, plus the market scale shaping what comes next.
Breast Cancers Statistics
With distant breast cancer showing only about a 28% 5 year relative survival in the United States, this page tracks how outcomes collide with risk factors that can be measured, modified, or treated. It pulls together current treatment trial results and prevention angles, including 685,000 breast cancer deaths worldwide in GBD 2019, plus how mammographic density, alcohol, obesity after menopause, and screening coverage help explain why risk can change dramatically between people.
Plantar Fasciitis Statistics
With about 10%–15% of adults dealing with plantar heel pain at any given time and MRI typically costing more than ultrasound by well over 2x for extremity imaging, this page connects real world burden to the economic and clinical tradeoffs behind conservative care, ESWT, splints, injections, and orthotics. You will also see how trial outcomes like pain VAS and foot function scales, plus adherence and recurrence rates, change the cost effectiveness story and explain why surgery stays uncommon.
Prescription Drug Overdose Statistics
Naloxone access and safer prescribing can change outcomes fast, yet prescription opioids still account for a major share of overdose deaths and misuse keeps overlapping with other high risk drugs like benzodiazepines. This page connects the latest U.S. overdose, dispensing, and misuse figures to show where the risk actually concentrates and what interventions appear to move the needle.
Hiv Aids Statistics
By the end of 2023, 39.9 million people were living with HIV globally, but women and girls still carry a disproportionate burden and young women aged 15 to 24 account for 25% of new adult infections. You will also see why prevention and treatment gains are uneven, from ART access for pregnant women to the persistent, high risk facing key populations and young people.
Concussion Statistics
Most people think concussion is a short recovery, yet 10% to 20% of adults still have symptoms beyond 3 months and women face a higher risk of lingering problems, with structured follow up delivered inconsistently despite guidance on relative rest and gradual return to activity. You will also see where the burden lands across age and settings, including 2.8 million estimated sport related concussions in the U.S. for ages 5 to 21, plus what early predictors like headache and vestibular symptoms suggest for who may need longer care.